ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Randomized Trial"

  • Abstract Number: 0411 • ACR Convergence 2022

    Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study

    Désirée van der Heijde1, Xenofon Baraliakos2, Maxime Dougados3, Matthew Brown4, Denis Poddubnyy5, Filip Van den bosch6, Nigil Haroon7, Huji Xu8, Tetsuya Tomita9, Lianne Gensler10, Marga Oortgiesen11, Carmen Fleurinck12, Natasha de Peyrecave13, Thomas Vaux14, Alexander Marten15 and Atul Deodhar16, 1Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 2Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 3Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, 4Genomics England, London, United Kingdom, 5Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 6Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, 7Schroeder Arthritis Institute, University Health Network; University of Toronto, Toronto, ON, Canada, 8Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China, 9Department of Orthopaedic Biomaterial Science, Osaka University Graduate School of Medicine, Osaka, Japan, Suita Osaka, Japan, 10Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, 11UCB Pharma, Raleigh, NC, 12UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, 13UCB Pharma, Brussels, Belgium, 14UCB Pharma, Slough, United Kingdom, 15UCB Pharma, Monheim am Rhein, Germany, 16Oregon Health & Science University, Portland, OR, USA, Portland, OR

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In a phase 2b study, BKZ showed rapid and…
  • Abstract Number: 1628 • ACR Convergence 2022

    The Sjogren Tool for Assessing Response (STAR): Assessment of Response Rates Overall, According to Baseline Activity and by Domain: Reanalysis of 9 Clinical Trials in Primary Sjogren Syndrome

    Raphaèle Seror1, Gabriel Baron2, Divi CORNEC3, Elodie Perrodeau2, Marine Camus4, Professor Simon Bowman5, Michele Bombardieri6, Hendrika Bootsma7, Suzanne Arends7, jacques-eric gottenberg8, Benjamin A. Fisher9, Wolfgang Hueber10, Joel Van Roon11, Valerie Devauchelle12, Liseth de Wolff13, Peter Gergely14, Xavier Mariette15 and Raphaël Porcher16, 1University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, 2AP-HP Hôtel Dieu Hospital, Université Paris Descartes, Paris, France, 3CHRU Brest, Brest, France, 4Department of Rheumatology, Université Paris-Saclay, APHP Hôpital Bicêtre, Le Kremlin Bicêtre, France, 5University Hospitals Birmingham, Birmingham, United Kingdom, 6Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, 7University Medical Center Groningen, Groningen, Netherlands, 8Strasbourg University Hospital, Strasbourg, France, 9University of Birmingham, Birmingham, United Kingdom, 10Novartis Pharmaceuticals, Basel, Switzerland, 11Rheumatology & Clinical Immunology, University of Utrecht, Utrecht, Netherlands, 12Université de Bretagne Occidentale, Brest, France, 13UMCG, Zwolle, Netherlands, 14Novartis Pharma, Basel, Switzerland, 15Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 16Université Paris Cité, Hôtel-Dieu, Paris, France

    Background/Purpose: The ESSDAI and ESSPRI, used alone, are not able to capture all features of primary Sjögren's syndrome (pSS). The NECESSITY consortium developed the Sjögren's…
  • Abstract Number: 2273 • ACR Convergence 2022

    Waning Vaccine Response After Primary Vaccine Series: Results from the Covid19 Vaccine Response in Rheumatology Patients (COVER) Study

    Amy Mudano1, Gary Cutter2, Ted Mikuls3, Geoffrey Thiele4, Mark Law4, Bart Hamilton4, Michael Zikry5, Kelly Y. Chun6, Monique Bastidas7, Michael George8, Lisa Williams9, Kevin Winthrop10, Mark Busch11, Stanley Cohen12, Roman Czubatyj13, Rajesh Kataria14, Reshma Khan15, Soha Mousa16, Jose Pando17, Elizabeth Perkins18, Shanmugapriya Reddy19, Delfin Santos20, Joy Schechtman21, Frank Scott22, Sucharitha Shanmugam23, Atul Singhal24, John Tesser25, John Tower26, Swamy Venuturupalli27, Sean Joseph Wollaston28, Conrad Ziembinski29 and Jeffrey Curtis30, 1Illumination Health, Hoover, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5LabCorp, Burlington, NC, 6Labcorp, Calabasas, CA, 7LabCorp, Northridge, CA, 8University of Pennsylvania, Philadelphia, PA, 9Illumination Heath, Hoover, AL, 10Oregon Health & Science University, Portland, OR, 11Family Arthritis Center-Jupiter, Jupiter, FL, 12Metroplex Clinical Research Center, Pittsburgh, PA, 13Arthritis Physicians LLC, Rochester Hills, MI, 14Southern Ohio, Wheelersburg, OH, 15Palm Beach Rheumatology and Wellness, Jupiter, FL, 16Arthritis and Rheumatology of Southwest Ohio, Liberty Township, OH, 17Rheumatology Consultants of DE, Lewes, DE, 18Rheumatology Care Center, Hoover, AL, 19Southwest Florida Rheumatology, Riverview, FL, 20Rochester Rheumatology, Rochester Hills, MI, 21SunValley Arthritis Center, Peoria, AZ, 22Arthritis Medical Center, Arroyo Grande, CA, 23Rheumatology and Arthritis Care Center, Exton, PA, 24Southwest Rheumatology Research, Mesquite, TX, 25Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 26Arthritis Physicians LLC, Rochester, MI, 27Cedars-Sinai Medical Center, Los Angeles, CA, 28Rheumatology Associates, North Hollywood, CA, 29CZ Rheumatology, Coral Springs, FL, 30Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Given possible increased risk of COVID-19 in patients with autoimmune conditions, there is a need to better understand the immunogenicity and safety of SARS-CoV-2…
  • Abstract Number: L05 • ACR Convergence 2021

    Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia

    Robert Terkeltaub1, JuneSik Mune2, Jieun Lee3 and Kenneth Saag4, 1VA/UCSD, San Diego, CA, 2LG Chem, Ltd., Seoul, 3LG Chem, Ltd., Seoul, South Korea, 4The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of…
  • Abstract Number: L10 • ACR Convergence 2021

    A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease

    joshua solomon1, Felix Woodhead2, Sonye Danoff3, Shana Haynes-Harp4, Tanvi Naik5, Cathie Spino5, Shelley Hurwitz6, Rie Maurer6, Daniel Chambers7, Martin Kolb8, Hiliary Goldberg6 and Ivan Rosas4, 1National Jewish Health, Denver, CO, 2University of Leicester, Leicester, United Kingdom, 3Johns Hopkins University, Baltimore, MD, 4Baylor College of Medicine, Houston, TX, 5University of Michigan, Ann Arbor, MI, 6Brigham and Womens Hospital, Boston, MA, 7University of Queensland, Brisbane, Australia, 8McMaster University, Hamilton, ON, Canada

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a prevalent and morbid condition leading to premature death in 10% of those affected. The TRAIL1 trial…
  • Abstract Number: L19 • ACR Convergence 2021

    Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial

    Nils Venhoff1, Wolfgang Schmidt2, Raoul Bergner3, Jürgen Rech4, Leonore Unger5, Hans-Peter Tony6, Meryl Mendelson7, Christian Sieder8, Meron Maricos8 and Jens Thiel9, 1Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany, 2Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Lindenberger Weg 19, 13125 Berlin, Germany, Berlin, Germany, 3Medizinische Klinik A, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany, 4Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, 5Medical Department 1, Städtisches Klinikum Dresden, Dresden, Germany, 6Department of Medicine 2, Rheumatology and Clinical Immunology Oberduerrbachertstr. 697080, Wuerzburg, Germany, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Pharma GmbH, Nuremberg, Germany, 9Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany; Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    Background/Purpose: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs…
  • Abstract Number: L21 • ACR Convergence 2021

    Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial

    Benjamin Terrier1, Gregory Pugnet2, Claire de Moreuil3, Bernard Bonnotte4, Ygal Benhamou5, Elisabeth Diot6, Dominique Chauveau2, Pierre Duffau7, Nicolas Limal8, Antoine Neel9, Geoffrey Urbanski10, Noemie Jourde-Chiche11, Nicolas Martin-Silva12, Francois Maurier13, Arsene Mekinian14, Nicolas Schleinitz11, Felix Ackermann15, Anne-Laure Fauchais16, Antoine Froissart17, Thomas Le Gallou18, Yurdagul Uzunhan19, Jean-Francois Viallard7, Alice Berezne20, Laurent Chiche21, Bruno Crestani14, Guillaume Direz22, Cecile-Audrey Durel23, Pascal Godmer24, Jean-Emmanuel Kahn25, Marc Lambert26, Thomas Quemeneur27, Jacques Cadranel14, Pierre Charles28, Antoine Dossier14, Lea Jilet29, Loic Guillevin14, Hendy Abdoul29 and Xavier Puechal14, 1Cochin Hospital, Paris, France, 2CHU, Toulouse, France, 3CHU, Brest, France, 4CHU, Dijon, France, 5CHU, Rouen, France, 6CHU, Tours, France, 7CHU, Bordeaux, France, 8CHU, Creteil, France, 9CHU, Nantes, France, 10CHU, Angers, France, 11CHU, Marseille, France, 12CHU, Caen, France, 13CH, Metz, France, 14CHU, Paris, France, 15Hopital Foch, Suresnes, France, 16CHU, Limoges, France, 17CHIC, Creteil, France, 18CHU, Rennes, France, 19CHU, Bobigny, France, 20CH, Annecy, France, 21CH, Marseille, France, 22CH, Le Mans, France, 23CHU, Lyon, France, 24CH, Vannes, France, 25CHU, Boulogne, France, 26CHRU, Lille, France, 27CH, Valenciennes, France, 28CH, Paris, France, 29URC, Paris, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic ANCA-associated vasculitis.Glucocorticoids, alone or in combination with cyclophosphamide in severe forms, induce remission in most patients…
  • Abstract Number: 0122 • ACR Convergence 2021

    Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management: A Randomized Controlled Trial

    Stephanie Catella1, Michael Gendreau2, Nicolette Vega1, Allison Kraus1, Michael Rosenbluth1, Sherry Soefje3, Shishuka Malhotra4 and Lesley Arnold5, 1Swing Therapeutics, San Francisco, CA, 2Gendreau Consulting, LLC, Poway, CA, 3Excell Research, Oceanside, CA, 4Neuro-Behavioral Clinical Research, North Canton, OH, 5University of Cincinnati, Cincinnati, OH

    Background/Purpose: Recommendations for fibromyalgia management include both pharmacologic and nonpharmacologic treatments. Cognitive behavioral therapy (CBT) has demonstrated level 1A evidence for fibromyalgia management, though access…
  • Abstract Number: 0837 • ACR Convergence 2021

    Sustainability of Response Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial

    Peter Nash1, Arthur Kavanaugh2, Maya Buch3, Bernard Combe4, Louis Bessette5, In-Ho Song6, Tim Shaw7, Yanna Song6, Jessica Suboticki6 and Roy Fleischmann8, 1Griffith University, Brisbane, Australia, 2University of California San Diego, La Jolla, CA, 3University of Leeds, Leeds, United Kingdom, 4CHU Montpellier Montpellier University, Montpellier, France, 5Laval University, Québec City, QC, Canada, 6AbbVie Inc., North Chicago, IL, 7AbbVie Inc., North Chicago, 8Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: The primary treatment target for patients with active rheumatoid arthritis (RA) is sustained clinical remission (REM) or low disease activity (LDA).1,2 A greater proportion…
  • Abstract Number: 1926 • ACR Convergence 2021

    Effectiveness of the Making It Work™ Program at Improving Absenteeism in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial

    Andre Luquini1, Yufei Zheng2, Hui Xie2, Catherine L. Backman3, Pamela Rogers4, Alex Kwok4, Astrid Knight4, Monique Gignac5, Dianne Mosher6, Linda Li3, John Esdaile7, Carter Thorne8 and Diane Lacaille2, 1University of British Columbia / Arthritis Research Canada, Fort Saint John, BC, Canada, 2Arthritis Research Canada, Richmond, BC, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4Arthritis Research Canada / UBC, Vancouver, BC, Canada, 5Institute for Work & Health, Toronto, ON, Canada, 6University of Calgary, Calgary, AB, Canada, 7Arthritis Research Canada, Vancouver, BC, Canada, 8Southlake Regional Health Centre, Newmarket, ON, Canada

    Background/Purpose: Despite advances in treatment, absenteeism remains a major problem for workers living with inflammatory arthritis (IA), leading to reduced income and quality of life.…
  • Abstract Number: 0183 • ACR Convergence 2021

    Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Phase 3, Randomized, Double-blind Clinical Trial for CsDMARD-IR and Bio-IR Patients

    Merav Lidar1, Jacob Aelion2, Gareth Scott Tarr3, Kim Papp4, Lisa Barcomb5, Ahmed M. Soliman5, Wenjing Lu6, Ann Eldred5 and Andrew Ostor7, 1Chaim Sheba Medical Center, Ramat Gan, Israel, 2Arthritis Clinic and West Tennessee Research Institute, Jackson, TN, 3Winelands Medical Research Centre and the Institute of Orthopaedics and Rheumatology (IOR), Winelands Medi-Clinic Orthopaedic Hospital, Stellenbosch, South Africa, 4K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, 5Abbvie Inc., North Chicago, IL, 6AbbVie Inc., North Chicago, 7Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia

    Background/Purpose: Risankizumab (RZB) is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. RZB is being investigated…
  • Abstract Number: 0924 • ACR Convergence 2021

    Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension

    Désirée van der Heijde1, Atul Deodhar2, Walter Maksymowych3, Joachim Sieper4, Filip Van den Bosch5, Tae-Hwan Kim6, Mitsumasa Kishimoto7, Andrew Ostor8, Bernard Combe9, Yunxia Sui10, Yuanyuan Duan11, Alvina D. Chu11 and In-Ho Song12, 1Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 2Oregon Health & Science University, Portland, OR, 3Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, 4Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 5Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, 6Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 7Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 8Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, 9Montpellier University, Montpellier, France, 10AbbVie, North Chicago, IL, 11AbbVie Inc, North Chicago, 12AbbVie Inc., North Chicago, IL

    Background/Purpose: The objective of this long-term analysis of the SELECT-AXIS 1 study was to report safety and efficacy of upadacitinib (UPA) in active AS through…
  • Abstract Number: 1940 • ACR Convergence 2021

    Malignancies in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

    Jeffrey Curtis1, Kunihiro Yamaoka2, Yi-Hsing Chen3, Levent M Gunay4, Naonobu Sugiyama5, Carol A Connell6, Cunshan Wang6, Joseph Wu6, Sujatha Menon6, Ivana Vranic7 and Juan J Gomez-Reino8, 1Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 2School of Medicine, Department of Rheumatology and Infectious Diseases, Kitasato University, Sagamihara, Japan, 3Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 4Pfizer Inc, Istanbul, Turkey, 5Pfizer Japan Inc, Tokyo, Japan, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, Tadworth, Surrey, United Kingdom, 8Hospital Clínico Universitario, Santiago de Compostela, Spain

    Background/Purpose: ORAL Surveillance (NCT02092467) was a post-authorization safety study to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based on observed increases in…
  • Abstract Number: 0193 • ACR Convergence 2021

    Tocilizumab for the Treatment of Familial Mediterranean Fever – a Randomized, Double Blind, Placebo-controlled Phase II Study

    Jorg Henes1, Sebastian Saur2, David Kofler3, Martin Krusche4, Theodoros Xenitidis5, Christoph Meisner6, Claudia Kedor7, Ina Koetter8, Hendrik Schulze-Koops9 and Eugen Feist10, 1University Hospital Tuebingen, Tuebingen, Germany, 2Universtiy Hostpiatl Tübingen, Tuebingen, Germany, 3Division of Rheumatology and Clinical Immunology, Department I of Internal Medicine; University Hospital Cologne, Cologne, Germany, 4Charite Berlin, Berlin, Germany, 5University Hospital Tuebingen, Rheumatology, Tuebingen, Germany, 6University Tuebingen, Statistics, Tuebingen, Germany, 7Charite University Hospital Berlin, Berlin, Germany, 8University Hospital Hamburg Eppendorf, Hamburg, Germany, 9Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 10Helios Department of Rheumatology, Vogelsang-Gommern, Germany

    Background/Purpose: Familial Mediterranean Fever (FMF) is the most common auto-inflammatory disease characterized by chronic inflammation, recurrent episodes of fever, abdominal and thoracic pain due to…
  • Abstract Number: 0957 • ACR Convergence 2021

    Vitamin D and Marine n-3 Fatty Acid Supplementation and Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial

    Jill Hahn1, Nancy Cook2, Erik Alexander3, Sonia Friedman3, Vadim Bubes3, Joseph Walter3, Gregory Kotler3, I-Min Lee3, JoAnn Manson3 and Karen Costenbader4, 1Harvard T.H. Chan School of Public Health, Boston, MA, 2Brigham and Womens' Hospital, Boston, MA, 3Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, 4Brigham and Women's Hospital, Belmont, MA

    Background/Purpose: In observational studies, vitamin D has been inconsistently associated with reduced risk of several autoimmune diseases, and a large randomized, controlled trial has been…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology